Compare INBK & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | PROF |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.0M | 248.8M |
| IPO Year | 2013 | 2017 |
| Metric | INBK | PROF |
|---|---|---|
| Price | $25.53 | $7.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $31.00 | $11.14 |
| AVG Volume (30 Days) | 37.2K | ★ 200.1K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ 1.10 | N/A |
| Revenue | $11,541,000.00 | ★ $16,098,000.00 |
| Revenue This Year | $18.83 | $69.27 |
| Revenue Next Year | $12.94 | $59.62 |
| P/E Ratio | $23.34 | ★ N/A |
| Revenue Growth | ★ 101.84 | 50.73 |
| 52 Week Low | $17.05 | $4.91 |
| 52 Week High | $31.09 | $8.95 |
| Indicator | INBK | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 71.11 |
| Support Level | $25.08 | $6.51 |
| Resistance Level | $26.09 | $7.92 |
| Average True Range (ATR) | 0.85 | 0.46 |
| MACD | -0.07 | 0.19 |
| Stochastic Oscillator | 19.43 | 92.47 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.